title: Stability of the patient acceptable symptomatic state over time in outcome criteria in ankylosing spondylitis.
abstract: OBJECTIVE
  The Patient Acceptable Symptomatic State (PASS) is the highest level of symptoms beyond which patients consider themselves well. It provides clinically meaningful information to interpret results from scales or questionnaires. Our goal was to determine the PASS in main outcome criteria when assessing patients with ankylosing spondylitis (AS) and to evaluate whether the PASS is stable over time.
  
  
  METHODS
  We used data from a randomized controlled trial of 330 patients with AS. The PASS was estimated at weeks 2, 6, and 12 for the following patient-reported outcomes: global pain (measured on a visual analog scale [VAS]), nocturnal pain (VAS), patient's global assessment of disease activity (VAS), disease activity (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI]), and functional impairment (Bath Ankylosing Spondylitis Functional Index [BASFI]). We used an anchoring method based on patients answering yes or no to, "Is your current condition satisfactory, when you take your general functioning and your current pain into consideration?" The PASS was defined as the 75th percentile of the score for patients who considered their state satisfactory. All patients were considered together in the analysis.
  
  
  RESULTS
  The values (95% confidence interval) of PASS were 33.5 (29.2-38.6) for pain, 28.0 (23.1-34.1) for night pain, 35.7 (31.3-41.1) for patient's global disease assessment, 31.4 (26.9-37.0) for BASFI, and 34.5 (30.9-38.9) for BASDAI. The PASS estimates were stable over time for all criteria during followup.
  
  
  CONCLUSIONS
  This study provides cutoff values for the PASS for the main outcome measures in AS and shows that PASS values are stable over time.
authors.affiliation: Assistance Publique-Hôpitaux de Paris, Bichat Hospital, University Paris VII, INSERM U738, Paris, France. florence.tubach@bch.aphp.fr
authors.forename: Florence
authors.initials: F
authors.lastname: Tubach
authors.forename: Thao
authors.initials: T
authors.lastname: Pham
authors.forename: Johan F
authors.initials: JF
authors.lastname: Skomsvoll
authors.forename: Knut
authors.initials: K
authors.lastname: Mikkelsen
authors.forename: Olav
authors.initials: O
authors.lastname: Bjørneboe
authors.forename: Philippe
authors.initials: P
authors.lastname: Ravaud
authors.forename: Maxime
authors.initials: M
authors.lastname: Dougados
authors.forename: Tore K
authors.initials: TK
authors.lastname: Kvien
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000068579:Celecoxib; D004008:Diclofenac / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006305:Health Status Indicators; D006801:Humans; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D017060:Patient Satisfaction; D011446:Prospective Studies; D011720:Pyrazoles / Q000627:therapeutic use; D012074:Remission Induction; D012720:Severity of Illness Index; D013167:Spondylitis, Ankylosing / Q000188:drug therapy / Q000503:physiopathology* / Q000523:psychology*; D013449:Sulfonamides / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D011720:Pyrazoles; D013449:Sulfonamides; D004008:Diclofenac; D000068579:Celecoxib